Navigation Links
Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
Date:4/16/2008

ing delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
2. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting
3. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
5. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
6. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
7. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
8. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
9. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
10. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
11. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted an additional abbreviated ... Drug Administration (FDA), which brings the Company,s total number ... submissions now pending at the FDA. ... Company, commented, "Our team here at IGI has continued ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, ... G.K. Butterfield (D-NC) took a bold bipartisan ... by introducing the OPEN Act. Original co-sponsors of ... (D-FL). The Act will incentivize drug makers and ... rare diseases and pediatric cancers, which opens the ...
(Date:11/24/2014)...   First published articles now ... Elsevier , a world-leading provider of scientific, technical and medical ... of the latest title in the Current Opinion journal ... . Current Opinion in ... to keep up-to-date with the expanding volume of information published ...
(Date:11/24/2014)... USA (PRWEB) November 23, 2014 One of ... field of optics and photonics is now available to high ... very low cost. SPIE, the international society for optics ... to the complete SPIE Digital Library available to ... price. , “Light-based technologies are integral to all areas of ...
Breaking Biology Technology:IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2
... June 23 Replidyne, Inc.,(Nasdaq: RDYN ) today ... with Asubio Pharma Co., Ltd. for faropenem medoxomil (faropenem).,In ... it has,terminated its supply agreement with Asubio Pharma Co., ... These decisions were made as a,result of the Company ...
... Web-based programs give sponsors easy-to-use tools to store, mine ... transfer knowledge base to ensure enrollment success, ... recruitment technology leader, announced the release of a new,product, ... support in-house recruitment capabilities for clinical,trial sponsors. The goal ...
... Ariz., June 23 MedPredict has published ... insight for pharma and,biotech companies hoping to ... The report, entitled "Thought Leader Insight & ... with a panel of,specialists in anesthesiology, psychiatry, ...
Cached Biology Technology:Replidyne Terminates Faropenem Agreements 2Replidyne Terminates Faropenem Agreements 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 2TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 4In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict 2
(Date:11/4/2014)... --   3D scanner developer ... Fuel3D , a developer of 3D scanning solutions, today ... million (£4 million). This funding builds on the company,s initial ... paves the way for the commercial launch of the company,s ... was led by Chimera Partners and will be used to ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... 2009)A minimally invasive interventional radiology treatmentthat safely and ... herniated diskswill become standard in the United States ... the Society of Interventional Radiology,s 34th Annual Scientific ... examined just how ozone relieves the pain associated ...
... once a week displayed higher cognitive skills at the age of ... a study of nearly 4,000 teenagers published in the March issue ... a week was enough to increase combined, verbal and visuospatial intelligence ... more than once a week increased them by just under 11 ...
... strokes has taken a significant step forward today (09 ... brain tissue in rats. The team of scientists ... Council (BBSRC) and led by Dr Mike Modo of ... work, carried out at the Institute of Psychiatry and ...
Cached Biology News:Oh, my aching back: Give me a shot of ozone 2Oh, my aching back: Give me a shot of ozone 3Teenage boys who eat fish at least once a week achieve higher intelligence scores 2Teenage boys who eat fish at least once a week achieve higher intelligence scores 3Stem cells replace stroke-damaged tissue in rats 2
... stretching or compression of a single cell ... so you can precisely regulate the degree ... 64 unique strain parameters. ST-160 has a ... models are compatible with Nikon, Olympus, Leica, ...
... Glycosylation is a post-translational modification ... biological functions, including immune regulation, inflammation, ... Biotechnology has developed two lectin based ... and Wheat Germ Agglutinin (WGA), that ...
... Pierce offers maleimide activated carrier ... hapten-carrier conjugates. Imject Maleimide Activated Carrier ... have been preactivated with a heterobifunctional ... a stable, sulfhydryl-reactive carrier protein. ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Biology Products: